NCT02079532View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

PHASE3CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Rheumatoid Arthritis
Interventions
DRUG

rituximab [MabThera]

1 g was given by intravenous infusion on Days 1 and 15

Trial Locations (69)

10117

Berlin

12200

Berlin

13055

Berlin

13125

Berlin

13589

Berlin

14163

Berlin

14929

Treuenbrietzen

18059

Rostock

22081

Hamburg

24351

Damp

24576

Bad Bramstedt

26121

Oldenburg

27404

Zeven

27476

Cuxhaven

28199

Bremen

30159

Hanover

30625

Hanover

35392

Giessen

36039

Fulda

37075

Göttingen

39245

Gommern

40211

Düsseldorf

40225

Düsseldorf

40882

Ratingen

41061

Mönchengladbach

42105

Wuppertal

44652

Herne

45239

Essen

45326

Essen

48149

Münster

48324

Sendenhorst

49074

Osnabrück

50924

Cologne

52146

Würselen

53111

Bonn

54292

Trier

55122

Mainz

55131

Mainz

58135

Hagen

58239

Schwerte

60590

Frankfurt am Main

65189

Wiesbaden

65191

Wiesbaden

65719

Hofheim

66424

Homburg/saar

67063

Ludwigshafen

69120

Heidelberg

70178

Stuttgart

72076

Tübingen

76135

Karlsruhe

78166

Donaueschingen

79106

Freiburg im Breisgau

80335

München

80336

München

81541

München

83043

Bad Aibling

89081

Ulm

91054

Erlangen

91056

Erlangen

93077

Bad Abbach

96047

Bamberg

97080

Würzburg

99096

Erfurt

01109

Dresden

06120

Halle

07743

Jena

02763

Mittelherwigsdorf

04683

Naunhof

01796

Pirna

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02079532 - A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor | Biotech Hunter | Biotech Hunter